DMAC News and Press, DiaMedica Therapeutics Inc. From 11/06/23

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Mon...

2023-10-25 07:29:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Wednesday and we’re offering up all the details about them that investors need to know about this morning. Moving stocks this morning are e...

2023-09-12 08:32:56 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics DiaMedica Therapeutics Inc. ( DMAC )...

Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatm...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7 th Annual Best Ideas ...

2023-08-15 15:43:02 ET DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript August 15 2023, 08:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital ...

2023-08-14 16:23:20 ET DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q2 GAAP EPS of -$0.16 beats by $0.02 . DiaMedica reported total cash, cash equivalents and investments of $60.7 million, current liabilities of $1.9 million and working capital of $39.3 milli...

Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M “At-The-Market” Private Placement, Cash Runway Into 2026 Company Co...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Mo...

2023-08-06 04:08:12 ET Summary DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing recombinant proteins to treat life-threatening diseases. Its main clinical candidate, DM199, is undergoing evaluation in a Phase 2/3 study for the treatment of...